Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Visceral Hypersensitivity in IBS
NCT03462966Phase 2Terminated
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Jul 2018
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rifaximin in irritable bowel syndrome (IBS), sponsored by Cedars-Sinai Medical Center. Primary endpoint: Mean Change in the Balloon Volume That Leads to First Urge to Defecate at 14 days. Started Jul 2018; status: terminated.
02
Drugs
rifaximin
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT03462966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03462966.